Seven Years of MiSight® 1 day: What We’ve Learned About Long-Term Myopia Control

Seven Years of MiSight® 1 day: What We’ve Learned About Long-Term Myopia Control

This article is brought to you by CooperVision ANZ, supporting healthy vision for Australian children.

Seven years of clinical research have confirmed what many optometrists now see in practice every day—MiSight® 1 day contact lenses offer sustained, and effective myopia control in children. Backed by CooperVision, this landmark study is the longest-running soft contact lens myopia management trial to date. It provides compelling evidence for optometrists seeking proven options for managing childhood myopia.

Part 1: The Foundational Years (Years 0–3)

The initial three-year phase of the MiSight® 1 day study was a prospective, multi-centre, double-masked, randomised controlled trial involving children aged 8–12. Participants wore either MiSight® 1 day lenses or single-vision contact lenses.

At the three-year mark, results showed a 52% reduction in axial elongation and a 59% reduction in myopia progression on average for those in the MiSight® 1 day group compared to the control group.¹ Notably, the effectiveness of the treatment was consistent across ages within the trial group, supporting early intervention at younger ages when myopia progresses most rapidly.

Part 2: The Crossover Phase (Years 4–6)

In year four, participants in the control group were switched to MiSight® 1 day lenses. These “delayed treatment” children showed similar slowing of myopia progression once on MiSight® lenses—demonstrating the lens’ effectiveness even when treatment starts later.²

Meanwhile, children who had been wearing MiSight® 1 day lenses from the beginning maintained ongoing reduction in progression, with no signs of treatment fatigue. Importantly, wearability and safety remained high: no significant adverse events related to contact lens wear occurred, and children continued to wear lenses comfortably and consistently, as reported in both clinical outcomes and parental feedback.³

Part 3: The Final Year and Beyond (Years 6–7)

The seventh year of the study examined what happens after stopping treatment. Children who had worn MiSight® 1 day lenses for six years were observed for 12 months without treatment. The key question: would they experience rebound effects?

The results were encouraging. The myopia control benefits were retained after treatment ended. While mild axial elongation continued, it aligned with typical age-related growth (on average, for children aged 8-15 at start of wear).⁴ These findings support the long-term durability of MiSight® 1 day’s myopia control benefits and provide confidence when making decisions about transitioning patients out of treatment.

Setting a Benchmark in Myopia Control

MiSight® 1 day remains the only soft contact lens approved by the U.S. FDA for slowing down the progression of myopia in children aged 8–12 years at treatment initiation. Use of MiSight® 1 day for myopia control in children is supported by seven years of data demonstrating it’s sustained effectiveness, excellent safety profile, and retention of myopia control benefits after treatment —offering optometrists a trusted tool in the fight against progressive myopia. For clinicians committed to evidence-based myopia management, MiSight® 1 day continues to be at the forefront.

¹Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96(8):556–567.

²Chamberlain P, et al. Myopia progression in children wearing dual‐focus contact lenses: 6‐year findings. Optom Vis Sci. 2021;98(3):211–219.

³Gifford K. Five things we know about MiSight. Myopia Profile. 2023. https://www.myopiaprofile.com/articles/five-things-we-know-about-misight_

 ⁴REF: Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7-year findings. OVS 2025 In Press;98:E-abstract 210049.]
[REF: Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. OVS 2021;98:E-abstract 215130.]